The peptide beauty boom could be worth $2.2billion more.. ...

Companies are racing to get ahead of the next wave of the peptide boom, as wellness firms and startups position themselves to meet a potential $2.2 billion surge in demand for weight loss and anti-aging treatments.

But the next leg up for the fast-moving industry depends on a looming Food and Drug Administration (FDA) decision.

The peptide goldrush has drawn telehealth platforms, compounding pharmacies and venture-backed startups in a rapidly expanding space that operates in a regulatory gray zone.

Much of the growth has been fueled by compounded or unapproved formulations, with companies arguing they are simply meeting demand that traditional drug development has failed to keep up with.

This has put the industry on a collision course with the FDA, whose next move could be a potential turning point.

The variety of peptides have proliferated, but the heart of the boom are DIY longevity treatments that are largely unapproved by the FDA and cannot sold for human use in the US.

Health and Human Services Secretary Robert F Kennedy Jr has thrown his support behind longevity peptides that will be reviewed for possible reclassification by the FDA, which industry insiders say could unlock a multibillion-dollar wellness surge.

Telehealth companies are already building out infrastructure around compounding pharmacies capable of producing experimental treatments at scale.

Companies are racing to get ahead of a $2.2 billion peptide boom, as wellness firms and startups rush to meet surging demand for weight loss and anti-aging treatments

The FDA’s Pharmacy Compounding Advisory Committee is set to meet in late July to consider whether to greenlight seven unapproved peptides for use in compounding pharmacies. A second hearing is planned for early next year to review additional compounds

In February 2025, Hims & Hers bought a peptide compounding facility in California, while Noom later acquired Tailor Made Compounding, which operates across 46 states.

Other companies are refusing to wait for regulatory action.

Some longevity clinics and physicians are already selling peptides directly to patients, sourcing compounds both domestically and overseas, a practice that has drawn growing scrutiny from regulators.

In May, the Alabama Board of Medical Examiners warned doctors against 'recommending, supplying, prescribing or administering these substances.'

Wilson Hunter, the board's general counsel, told the Wall Street Journal that the warning followed a rise in unapproved peptides showing up in audits, investigations and patient complaints.

'We're not anti-peptide,' he said. 'We're just anti-people hurting themselves because they're getting products that aren't vetted or verified.'

The FDA's Pharmacy Compounding Advisory Committee will meeting in late July to consider whether to greenlight seven unapproved peptides - including BPC-157 - for use in compounding pharmacies, with a second hearing planned for early next year to review additional compounds.

The agency previously added the substances to a restricted compounding list in 2023, citing insufficient safety data, before later removing them earlier this year.

Several peptides will be reviewed for reclassification with backing from Health and Human Services Secretary Robert F Kennedy Jr

Some longevity clinics and physicians are already selling peptides directly to patients, sourcing compounds both domestically and overseas

Mino, a new platform linking clinicians, doctors and med spas with peptide suppliers, recently acquired a South Carolina facility licensed across multiple states, according to its founders.

The site once produced 'research use only' compounds, which CEO Elizabeth Straus told the WSJ reflected its former model. The company now promotes what it calls 'pharmaceutical-grade inputs.'

A spokesperson for the US Department of Health and Human Services told the WSJ that rising black market use and public interest 'do not change the FDA's scientific or regulatory standards,' pointing to the agency's existing review process and upcoming hearings.

Protocole, a peptide-focused telehealth startup founded in 2025, raised $6 million in April and markets itself as avoiding unregulated 'research use only' products entirely.

Patients pay around $200 to $300 per peptide, which includes a consultation with a clinician to guide use.

Its founders, Delphine Le Grand and Cindy Yan, previously worked at a longevity clinic in New York. On social media, Yan has promoted the effects of GHK-Cu - known as the 'beauty peptide' - on skin health.

But regulatory experts warn the industry is still operating in a legal grey zone.

Bill Holtz, a FDA regulatory strategist at Foley & Lardner LLP, told the WSJ that compounding pharmacies producing some of these peptides are doing so without explicit FDA approval.

He said regulators are now trying to balance consumer demand with safety concerns in a fast-moving market where oversight is still catching up.